Information  X 
Enter a valid email address

EKF Diagnostics Hldg (EKF)

  Print      Mail a friend

Tuesday 23 October, 2018

EKF Diagnostics Hldg

Update to distribution timetable

RNS Number : 9047E
EKF Diagnostics Holdings PLC
23 October 2018

EKF Diagnostics Holdings plc

("EKF" or the "Company") 


Update to distribution timetable


Following the release of the Company's announcement on 22 October 2018, the Company provides the below update in relation to its planned distribution timetable.


The updated anticipated timetable for the distribution is set out below:


Record date for the Distribution

Close of business on 23 October

EKF ordinary shares marked as ex rights

 8.00am on 24 October

Distribution declared by the board of directors

24 October

Admission of issued and to be issued RENX Shares to trading on AIM

2 November


End of Lock-up Period

22 April


EKF shareholders on the register at close of business on 23 October 2018 ("Relevant EKF Shareholders") will receive one RENX Share for every 21.825 EKF ordinary shares held.


All times and dates in this announcement may be subject to change.





EKF Diagnostics Holdings plc 

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO
Richard Evans, FD & COO


N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)


Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303




About EKF Diagnostics Holdings plc

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t